Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selenium and cholecalciferol added to methimazole in Graves' hyperthyroidism
2017-005050-11Phase 4Completed
- Sponsor
- ASST Sette Laghi
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Graves' disease and hyperthyroidism comparing Methimazole standard therapy with Methimazole plus selenium and cholecalciferol (2 arms). Primary endpoint: Biochemical and clinical hyperthyroidism status at 180 days. Started Sep 2021; status: completed.
02
Drugs
seleniumvitamin dmethimazole
03
Conditions
Graves' diseasehyperthyroidism
Beyond the preview
Go deeper on 2017-005050-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005050-11.